Bruce L. Levine

faculty photo
Barbara and Edward Netter Professor in Cancer Gene Therapy
Abramson Cancer Center of the University of Pennsylvania (Member), Abramson Cancer Center of the University of Pennsylvania (Member)
Department: Pathology and Laboratory Medicine

Contact information
M6.40 Maloney Building
Hospital of the University of Pennsylvania
3400 Spruce Street
Philadelphia, PA 19104-4268
Office: (215)-573-6788
Fax: 215-615-4718
B.A. (Major-Biology, Minor-History)
The University of Pennsylvania , 1984.
Ph.D. (Immunology and Infectious Diseases)
The Johns Hopkins University, 1992.
Permanent link

Description of Research Expertise

Immunology, Cell and Gene Therapy

Description of Other Expertise

Good Manufacturing Practices

Description of Itmat Expertise

Dr. Levine's interests include cell, gene, and biologic therapy clinical trial development, manufacturing, and testing and lymphocyte growth, activation and senescence.

Selected Publications

Rapoport, AP, Aqui, NA, Stadtmauer, EA, Vogl, DT, Xu, YY, Kalos, M, Cai, L, Fang, H-B, Weiss, BM, Badros, A, Yanovich, S, Akpek, G, Cross, A, Mann, A, Philip, S, Kerr, N, Brennen, A, Zheng, Z, Ruehl, K, Milliron, T, Strome, SE, Salazar, AM, Levine, BL, June, CH: Combination immunotherapy after ASCT for multiple myeloma (MM) using MAGE-A3/Poly-ICLC immunizations followed by vaccine-primed and costimulated autologous T-Cells. Clinical Cancer Research 20(5): 1355, March 2014.

Tebas Pablo, Stein David, Tang Winson W, Frank Ian, Wang Shelley Q, Lee Gary, Spratt S Kaye, Surosky Richard T, Giedlin Martin A, Nichol Geoff, Holmes Michael C, Gregory Philip D, Ando Dale G, Kalos Michael, Collman Ronald G, Binder-Scholl Gwendolyn, Plesa Gabriela, Hwang Wei-Ting, Levine Bruce L, June Carl H: Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. The New England Journal of Medicine 370(10): 901-10, Mar 2014.

Beatty Gregory L, Haas Andrew R, Maus Marcela V, Torigian Drew A, Soulen Michael C, Plesa Gabriela, Chew Anne, Zhao Yangbing, Levine Bruce L, Albelda Steven M, Kalos Michael, June Carl H: Mesothelin-specific Chimeric Antigen Receptor mRNA-Engineered T cells Induce Anti-Tumor Activity in Solid Malignancies. Cancer immunology research 2(2): 112-120, Feb 2014.

Beatty, G.L., Haas, A.R., Maus, M.V., Torigian, D.A., Soulen, M.C., Zhao, Y., Levine, B.L., Albelda, S.M., Kalos, M., June, C.H.: Mesothelin-specific Chimeric Antigen Receptor mRNA-Engineered T cells Induce Anti-Tumor Activity in Solid Malignancies. Cancer Immunology Research 2(2): 1-9, December 2013 Notes: DOI: 10.1158/2326-6066.CIR-13-0170.

Cameron, BJ, Gerry, AB, Dukes, J, Harper, JV, Kannan, V, Bianchi, FC, Grand, F, Brewer, JE, Gupta, M, Plesa, G, Bossi, G, Vuidepot, A, Powlesland, AS, Legg, A, Adams, KJ, Bennett, AD, Pumphrey, NJ, Williams, DD, Binder-Scholl, G, Kulikovskaya, I, Levine, BL, Riley, JL, Varela-Rohena, A, Stadtmauer, EA, Rapoport, AP, Linette, GP, June, CH, Hassan, NJ, Kalos, M, Jakobsen, BK: Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells. Science Translational Medicine 5(197): 197ra103, August 2013.

Kumar AJ, Hexner EO, Frey NV, Luger SM, Loren AW, Reshef R, Boyer J, Smith J, Stadtmauer EA, Levine BL, June CH, Porter DL, Goldstein SC: Pilot Study of Prophylactic Ex Vivo Co-Stimulated Donor Leukocyte Infusions After Reduced Intensity Conditioned Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplant 19(7): 1094–1101, July 2013 Notes: 2013 Apr 28. doi:pii: S1083-8791(13)00189-4. 10.1016/j.bbmt.2013.04.021. [Epub ahead of print]

Chiang CL, Kandalaft L, Tanyi JL, Hagemann AR, Motz GT, Svoronos N, Montone K, Mantia-Smaldone GM, Nisenbaum HL, Levine BL, Kalos M, Czerniecki BJ, Torigian DA, Powell DJ Jr, Mick R, Smith L, Coukos G: A Dendritic Cell Vaccine Pulsed with Autologous Hypochlorous Acid-Oxidized Ovarian Cancer Lysate Primes Effective Broad Antitumor Immunity: From Bench to Bedside. Clinical Cancer Research July 2013 Notes: Published OnlineFirst on July 9, 2013; DOI: 10.1158/1078-0432.CCR-13-118.

Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, Litzky L, Bagg A, Carreno BM, Cimino PJ, Binder-Scholl GK, Smethurst DP, Gerry AB, Pumphrey NJ, Bennett AD, Brewer JE, Dukes J, Harper J, Tayton-Martin HK, Jakobsen BK, Hassan NJ, Kalos M, June CH: Cardiovascular toxicity and titin cross-reactivity of affinity enhanced T cells in myeloma and melanoma. Blood June 2013 Notes: doi:10.1182/blood-2013-03-490565.

Grupp, SA, Kalos, M, Barrett, D, Aplenc, R, Porter, DL, Rheingold, SR, Teachey, DT, Chew, A, Hauck, B, Wright, JF, Milone, MC, Levine, BL, June, CH: Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia. New England Journal of Medicine 368(16): 1509-18, April 2013 Notes: doi: 10.1056/NEJMoa1215134. Epub 2013 Mar 25.

Fowler DH, Mossoba ME, Steinberg SM, Halverson DC, Stroncek D, Khuu HM, Hakim FT, Castiello L, Sabatino M, Leitman SF, Mariotti J, Gea-Banacloche JC, Sportes C, Hardy NM, Hickstein DD, Pavletic SZ, Rowley S, Goy A, Donato M, Korngold R, Pecora A, Levine BL, June CH, Gress RE, Bishop MR: Phase II clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation. Blood February 2013 Notes: ePub ahead of print, doi: 10.1182/blood-2012-08-446872.

back to top
Last updated: 08/13/2014
The Trustees of the University of Pennsylvania